Antiviral effect of Bosentan and Valsartan during coxsackievirus B3 infection of human endothelial cells

Funke C, Farr M, Werner B, Dittmann S, Überla K, Piper C, Niehaus K, Horstkotte D (2010)
Journal of General Virology 91(8): 1959-1970.

Journal Article | Published | English

No fulltext has been uploaded

Author
; ; ; ; ; ; ;
Abstract
In viral myocarditis, adeno- and enteroviruses have most commonly been implicated as causes of infection. Both viruses require the human coxsackie-adenovirus receptor (CAR) to infect the myocardium. Due to its crucial role for viral entry, CAR-downregulation may lead to novel approaches for treatment for viral myocarditis. In this study, we report on pharmaceutical drug influences on CAR levels in human umbilical vein endothelial cells (HUVEC) and cervical carcinoma cells (HeLa) detected by immunoblotting, quantitative real time-PCR and cellular susceptibility to the cardiotropic coxsackie-B3 virus strain Nancy (CVB3). Our results indicate, for the first time, a dose-dependent CAR mRNA and protein downregulation upon Valsartan and Bosentan treatment. Most interestingly, drug-induced CAR diminution significantly reduced the viral load in CVB3-infected HUVEC. In order to assess the regulatory effects of both drugs in detail, we knocked down their protein targets, the G-protein coupled receptors angiotensin-II type-1 receptor (AT(1)R) and endothelin-1 type-A and -B receptors (ETAR/ETBR) in HUVEC. Receptor-specific gene silencing indicates that CAR gene expression is regulated by agonistic and antagonistic binding to ETBR, but not ETAR. In addition, neither stimulation nor inhibition of AT(1)R seemed to be involved in CAR gene regulatory processes. Our study indicates that Valsartan and Bosentan protected human endothelial cells from CVB3-infection. Therefore, besides their well-known anti-hypertensive effects these drugs may also protect the myocardium and other tissues from coxsackie- and adenoviral infection.
Publishing Year
ISSN
eISSN
PUB-ID

Cite this

Funke C, Farr M, Werner B, et al. Antiviral effect of Bosentan and Valsartan during coxsackievirus B3 infection of human endothelial cells. Journal of General Virology. 2010;91(8):1959-1970.
Funke, C., Farr, M., Werner, B., Dittmann, S., Überla, K., Piper, C., Niehaus, K., et al. (2010). Antiviral effect of Bosentan and Valsartan during coxsackievirus B3 infection of human endothelial cells. Journal of General Virology, 91(8), 1959-1970.
Funke, C., Farr, M., Werner, B., Dittmann, S., Überla, K., Piper, C., Niehaus, K., and Horstkotte, D. (2010). Antiviral effect of Bosentan and Valsartan during coxsackievirus B3 infection of human endothelial cells. Journal of General Virology 91, 1959-1970.
Funke, C., et al., 2010. Antiviral effect of Bosentan and Valsartan during coxsackievirus B3 infection of human endothelial cells. Journal of General Virology, 91(8), p 1959-1970.
C. Funke, et al., “Antiviral effect of Bosentan and Valsartan during coxsackievirus B3 infection of human endothelial cells”, Journal of General Virology, vol. 91, 2010, pp. 1959-1970.
Funke, C., Farr, M., Werner, B., Dittmann, S., Überla, K., Piper, C., Niehaus, K., Horstkotte, D.: Antiviral effect of Bosentan and Valsartan during coxsackievirus B3 infection of human endothelial cells. Journal of General Virology. 91, 1959-1970 (2010).
Funke, Carsten, Farr, Martin, Werner, Bianca, Dittmann, Sven, Überla, Klaus, Piper, Cornelia, Niehaus, Karsten, and Horstkotte, Dieter. “Antiviral effect of Bosentan and Valsartan during coxsackievirus B3 infection of human endothelial cells”. Journal of General Virology 91.8 (2010): 1959-1970.
This data publication is cited in the following publications:
This publication cites the following data publications:

3 Citations in Europe PMC

Data provided by Europe PubMed Central.

Characterization of coxsackievirus B3 replication in human umbilical vein endothelial cells.
Kuhnl A, Rien C, Spengler K, Kryeziu N, Sauerbrei A, Heller R, Henke A., Med. Microbiol. Immunol. 203(4), 2014
PMID: 24615265
Effect of lovastatin on coxsackievirus B3 infection in human endothelial cells.
Werner B, Dittmann S, Funke C, Uberla K, Piper C, Niehaus K, Horstkotte D, Farr M., Inflamm. Res. 63(4), 2014
PMID: 24316867
Dioscin's antiviral effect in vitro.
Liu C, Wang Y, Wu C, Pei R, Song J, Chen S, Chen X., Virus Res. 172(1-2), 2013
PMID: 23238077

39 References

Data provided by Europe PubMed Central.

Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788.
Ishikawa K, Ihara M, Noguchi K, Mase T, Mino N, Saeki T, Fukuroda T, Fukami T, Ozaki S, Nagase T., Proc. Natl. Acad. Sci. U.S.A. 91(11), 1994
PMID: 8197152
Presentation, patterns of myocardial damage, and clinical course of viral myocarditis.
Mahrholdt H, Wagner A, Deluigi CC, Kispert E, Hager S, Meinhardt G, Vogelsberg H, Fritz P, Dippon J, Bock CT, Klingel K, Kandolf R, Sechtem U., Circulation 114(15), 2006
PMID: 17015795
Coxsackievirus entry across epithelial tight junctions requires occludin and the small GTPases Rab34 and Rab5.
Coyne CB, Shen L, Turner JR, Bergelson JM., Cell Host Microbe 2(3), 2007
PMID: 18005733
The Coxsackievirus and Adenovirus Receptor
Freimuth, 2008
Acute viral myocarditis
Dennert, European Heart Journal 29(17), 2008
The tight junction protein CAR regulates cardiac conduction and cell-cell communication.
Lisewski U, Shi Y, Wrackmeyer U, Fischer R, Chen C, Schirdewan A, Juttner R, Rathjen F, Poller W, Radke MH, Gotthardt M., J. Exp. Med. 205(10), 2008
PMID: 18794341
Bosentan enhances viral load via endothelin-1 receptor type-A-mediated p38 mitogen-activated protein kinase activation while improving cardiac function during coxsackievirus-induced myocarditis.
Marchant D, Dou Y, Luo H, Garmaroudi FS, McDonough JE, Si X, Walker E, Luo Z, Arner A, Hegele RG, Laher I, McManus BM., Circ. Res. 104(6), 2009
PMID: 19213955
Cardiac deletion of the Coxsackievirus-adenovirus receptor abolishes Coxsackievirus B3 infection and prevents myocarditis in vivo.
Shi Y, Chen C, Lisewski U, Wrackmeyer U, Radke M, Westermann D, Sauter M, Tschope C, Poller W, Klingel K, Gotthardt M., J. Am. Coll. Cardiol. 53(14), 2009
PMID: 19341864
Viral myocarditis: from the perspective of the virus.
Yajima T, Knowlton KU., Circulation 119(19), 2009
PMID: 19451363
Tissue-specific deletion of the coxsackievirus and adenovirus receptor protects mice from virus-induced pancreatitis and myocarditis.
Kallewaard NL, Zhang L, Chen JW, Guttenberg M, Sanchez MD, Bergelson JM., Cell Host Microbe 6(1), 2009
PMID: 19616768
Prevention of cardiac dysfunction in acute coxsackievirus B3 cardiomyopathy by inducible expression of a soluble coxsackievirus-adenovirus receptor.
Pinkert S, Westermann D, Wang X, Klingel K, Dorner A, Savvatis K, Grossl T, Krohn S, Tschope C, Zeichhardt H, Kotsch K, Weitmann K, Hoffmann W, Schultheiss HP, Spiller OB, Poller W, Fechner H., Circulation 120(23), 2009
PMID: 19933937

Export

0 Marked Publications

Open Data PUB

Web of Science

View record in Web of Science®

Sources

PMID: 20392896
PubMed | Europe PMC

Search this title in

Google Scholar